Notice Number: NOT-CA-20-037
Release Date: March 23, 2020
First Available Due Date: May 15, 2020
Expiration Date: May 16, 2020
National Cancer Institute (NCI)
This Notice of Special Interest informs current National Cancer Institute (NCI) grant awardees that NCI is interested in administrative supplement applications that seek to address gaps in knowledge pertaining to the effects of a cancer diagnosis and its treatment on aging trajectories among adult cancer survivors (including adult survivors of pediatric cancers).
With the advent of successful screening strategies and more effective treatments, cancer survivors are now living longer. However, this success has come with a cost -- the treatments that cancer survivors are administered have been shown in laboratory studies to cause cell damage through many of the same mechanisms that are thought to underlie the normal aging process. Thus, the treatments that spare cancer survivors from mortality related to their cancer may adversely alter their aging trajectory, putting the cancer survivor at risk for a broad spectrum of aging-related health conditions at a younger age than would occur with the normal aging process. While this is biologically plausible, there is a paucity of studies that have examined whether the molecular and cellular changes resulting from treatment toxicity change a cancer survivor’s aging trajectory.
NCI currently supports a scientifically diverse cancer survivorship grant portfolio, including a number of cancer survivor cohort studies and intervention trials that follow individuals diagnosed with cancer over time to examine the effects of treatment, and other factors, on cancer outcomes (e.g. survival, recurrence, late- and long-term adverse events). Often, the outcome data in these cancer survivor studies do not include data related to aging (e.g., frailty, physical functioning). Through this administrative supplement opportunity, NCI expects that applicants will strengthen their currently funded aims by collecting information on cancer, cancer treatment, and/or aging-related endpoints (including those measured in biospecimens) to address existing gaps in knowledge regarding cancer and aging trajectories. The supplemental funding request be for work that enhances the research within the scope of the parent award by relating it to the aging-related effects of cancer and its treatments.
NCI encourages collaborative research among transdisciplinary research teams that include (but are not limited to) epidemiologists, clinical trialists, basic scientists, and behavioral and social scientists. NCI also encourages data sharing and the integration of existing data resources to enable novel approaches to address the complex nature of the longitudinal data needed to examine aging trajectories.
In the context of this opportunity, NCI’s interests include, but are not limited to:
Eligible Individuals (Program Director/Principal Investigator):
Individual(s) must hold an active eligible NCI grant (R01, U01, R37, P01, U19, or UM1). For supplements to parent awards that include multiple program directors (PDs)/principal investigators (PIs), the supplement may be requested by any or all of the PDs/PIs (in accordance with the existing leadership plan) and submitted by the awardee institution of the parent award.
Description of circumstances for which administrative supplements are available.
Application and Submission Information
Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent.
Applicants should also inform Dr. Lisa Gallicchio (email: firstname.lastname@example.org) of the submission to ensure correct routing.
Administrative Review Process:
NCI will conduct administrative reviews of applications submitted to this FOA and will support the most meritorious applications submitted for consideration, based upon availability of funds.
NCI staff will consider the ability of the proposed supplement activities to increase or preserve the parent award’s overall impact within the original scope of the award. Primary considerations include, but are not limited to, the following:
Additional selection factors include:
Please direct all inquiries to: